What Happened?
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
When macroeconomic uncertainty weighs on the broader market, investors often rotate capital into defensive sectors that offer steady demand regardless of the economic cycle. Healthcare has historically provided resilience because medical care, diagnostics, and clinical treatments remain essential needs. This steady inflow has pushed valuations across the sector to a premium as market participants seek shelter during volatile periods. Concurrently, advancements in healthcare technology and data-driven initiatives continue to support long-term sector fundamentals.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Therapeutics company Moderna (NASDAQ: MRNA) jumped 8.5%. Is now the time to buy Moderna? Access our full analysis report here, it’s free.
- Genomics & Sequencing company 10x Genomics (NASDAQ: TXG) jumped 4.1%. Is now the time to buy 10x Genomics? Access our full analysis report here, it’s free.
- Health Insurance Providers company Oscar Health (NYSE: OSCR) jumped 1.2%. Is now the time to buy Oscar Health? Access our full analysis report here, it’s free.
- Therapeutics company Novavax (NASDAQ: NVAX) jumped 4.5%. Is now the time to buy Novavax? Access our full analysis report here, it’s free.
Zooming In On Moderna (MRNA)
Moderna’s shares are extremely volatile and have had 57 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 8 days ago when the stock dropped 2.9% on the news that Rothschild & Co Redburn analyst Simon Baker downgraded the company to Sell from Neutral on valuation concerns. Baker raised Moderna's price target to $81 from $40, representing a 46% downside from the previous day’s close of $150.81, CNBC reported. The downgrade followed positive results from the Phase 3 INTerpath-001 trial of Moderna's cancer vaccine candidate, intismeran autogene, evaluated in combination with Keytruda, the company said. While Baker called the melanoma data "undoubtedly good" in a note to clients, he argued that the stock's "overexuberant reaction" was unjustified.
Moderna is up 380% since the beginning of the year, but at $148.14 per share, it is still trading 15% below its 52-week high of $174.38 from August 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at only $352.94.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
